New drug shows promise for slowing rare neurological disease

NCT ID NCT02255435

Completed Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

Summary

This study tested a drug called omaveloxolone (RTA 408) to see if it could help people with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. Researchers enrolled 172 participants to measure the drug's safety and its effects on physical effort and daily function over 48 weeks. The goal was to see if the drug could help control the progression of the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Emory University Hospital - Neurology

Atlanta, Georgia, 30329, United States
Medical University Innsbruck

Innsbruck, 6020, Austria
Murdoch Childrens Research Institute

Parkville, Victoria, 3052, Australia
Neurological Institute Carlo Besta

Milan, 20133, Italy
Ohio State University - Neurology

Columbus, Ohio, 43221, United States
UCLA

Los Angeles, California, 90095, United States
USF Ataxia Research Center

Tampa, Florida, 33612, United States
University College of London

London, WC1E 6BT, United Kingdom
University of Florida - Neurology

Gainesville, Florida, 32610, United States
University of Iowa Stead Family Children's Hospital

Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.

FRIEDREICH ATAXIA